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ABSTRACT 24 
Candida glabrata is intrinsically less susceptible to azoles and resistance to echinocandins and 25 
reduced susceptibility to amphotericin B has also been detected. Molecular mechanisms of 26 
reduced susceptibility (RS) to amphotericin B (AMB) were investigated in C. glabrata strains in 27 
Kuwait by sequence analyses of genes involved in ergosterol biosynthesis. A total of 1646 C. 28 
glabrata isolates were tested by Etest and results for 12 selected isolates were confirmed by 29 
reference broth microdilution. PCR-sequencing of three (ERG2, ERG6 and ERG11) genes was 30 
performed for all RS-AMB and 5 selected wild-type C. glabrata isolates by using gene-specific 31 
primers. Total cell sterol content was analyzed by gas chromatography-mass spectrometry. 32 
Phylogenetic relationship among the isolates was investigated by multilocus sequence typing. 33 
Wild-type isolates contained only synonymous mutations in ERG2, ERG6 or ERG11 and total 34 
sterol content was similar to reference strains. A nonsynonymous (AGA48AAA, R48K) ERG6 35 
mutation was found in both RS-AMB and wild-type isolates. Four RS-AMB isolates contained 36 
novel nonsense mutations at Trp286/Tyr192/Leu341 and 2 isolates contained nonsynonymous 37 
(V126F or C198F) mutation in ERG6 and their sterol content were consistent with ERG6 38 
deficiency. Two other RS-AMB isolates contained a novel nonsynonymous (G119S or G122S) 39 
ERG2 mutation and their sterol content were consistent with ERG2 deficiency. Of 8 RS-AMB 40 
isolates, 1 fluconazole-resistant isolate also contained nonsynonymous Y141H+L381M 41 
mutations while 7 isolates contained only synonymous mutations in ERG11. All isolates with 42 
ERG6/ERG2/ERG11 mutations were genotypically distinct strains. Our data show that ERG6 and 43 
ERG2 are major targets conferring RS-AMB in clinical C. glabrata isolates.  44 
 45 
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INTRODUCTION 49 
Candida species are the most common cause of invasive fungal infections in seriously ill or 50 
immunocompromised hospitalized patients (1). Although Candida albicans is the most 51 
pathogenic species, infections by non-albicans Candida species have increased in recent years 52 
and are associated with high mortality rates (1-3). Candida glabrata is the second or third most 53 
commonly isolated yeast species causing candidemia and other invasive infections in critically ill 54 
older adult (>65 years) patients (1-3). C. glabrata is intrinsically less susceptible to azole 55 
antifungal drugs and causes mortality in nearly 50% subjects with invasive infections (2-4). 56 
Recent years have also witnessed increasing reports of breakthrough C. glabrata infections in 57 
patients receiving systemic echinocandin (micafungin) or polyene treatment (5-7). 58 
Major antifungal drugs used for invasive Candida infections include triazoles (such as 59 
fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole), echinocandins (such 60 
as caspofungin, anidulafungin and micafungin) and polyenes (such as amphotericin B, AMB and 61 
liposomal amphotericin B, LAMB). In contrast to azoles and echinocandins which disrupt 62 
ergosterol and glucan synthesis, respectively, polyenes were postulated, until recently, to 63 
intercalate directly with membrane ergosterol forming ion channels, which permeabilize and kill 64 
yeast cells (3, 4). More recent studies, however, have shown that AMB forms extramembranous 65 
aggregates which extract ergosterol, a central molecule in yeast physiology, from phospholipid 66 
bilayers like a sterol sponge and removal of ergosterol kills yeast cells while the contribution of 67 
ion channels is relatively minor (8). The sterol sponge model has also stipulated that 68 
simultaneous extraction of cholesterol by AMB from mammalian cells is responsible for its 69 
toxicity suggesting the possibility of separating cytocidal properties from membrane 70 
permeabilizing activities (8). Further studies have indeed resulted in the synthesis of other 71 
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derivatives of AMB (such as amphotericin B methyl urea and amphotericin B amino urea) that 72 
bind ergosterol with much greater selectivity than cholesterol and thus are toxic to yeast cells but 73 
not to human cells (9). 74 
Consistent with their mechanism of action, resistance of Candida spp. to triazoles and 75 
echinocandins usually develops in a stepwise manner during prolonged therapy as a result of 76 
induced changes and mutations (3, 4, 10). Since extraction of ergosterol by AMB from yeast 77 
membranes will affect all ergosterol-dependent cellular processes and membrane 78 
fluidity/hydrophobicity, evolution of amphotericin B-resistant strains is expected to be highly 79 
unlikely due to involvement of many different membrane proteins that directly bind to ergosterol 80 
as well as blocking of transport processes by several essential transport proteins due to alteration 81 
in membrane properties (11). Thus, emergence of Candida spp. exhibiting reduced susceptibility 82 
to AMB (RS-AMB) has generally been rare despite >50 years of clinical use. The mutations in 83 
rare RS-AMB C. albicans strains created defects in filamentation and tissue invasion and diverse 84 
stresses resulting in hypersensitivity to oxidative stress, febrile temperatures and neutrophil-85 
mediated killing (12, 13). On the contrary, increasing reports of RS-AMB in C. glabrata, a 86 
haploid species, is a worrisome development (14-19). 87 
Given the lower susceptibility to azoles and increasing incidence of breakthrough 88 
infections in patients on micafungin therapy, reduced susceptibility to polyenes will severely 89 
limit the choice of antifungal drugs to treat C. glabrata infections (3, 4). Since polyenes extract 90 
ergosterol from the cell membrane, changes in ergosterol content due to mutations in ERG genes 91 
involved in ergosterol biosynthesis alter susceptibility to polyenes and complete absence of 92 
ergosterol confers RS-AMB (17, 19, 20). A better understanding of the mechanisms that mediate 93 
reduced susceptibility to polyenes in C. glabrata is warranted. The first molecular mechanism 94 
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describing RS-AMB in C. glabrata involved a missense (C198F) or a nonsense (at Gln332) 95 
mutation in ERG6 encoding C24-methyl transferase that converts zymosterol to fecosterol in 96 
ergosterol biosynthesis pathway (15, 17). Deletion of ERG11 or mutations in ERG1, ERG2 and 97 
ERG11 have also been described that are associated with RS-AMB in C. glabrata (18, 19, 21). 98 
Lack of ERG6 and ERG2 encoded enzyme activities leads to accumulation of zymosterol and 99 
fecosterol, respectively. Zymosterol and fecosterol can support fungal cell growth and absence of 100 
ergosterol in Candida cell membrane confers RS-AMB (15, 17, 19, 22).  101 
Epidemiological cut-off values rather than clinical breakpoints are available for 102 
interpreting the minimum inhibitory concentrations (MICs) of AMB for Candida species and 103 
yeasts with MICs of <2 µg/ml were classified as wild-type (WT) while isolates with MICs >2 104 
µg/ml were defined as non-wild-type (non-WT) (23). Antifungal drug susceptibility testing 105 
(AST) data for clinical C. glabrata isolates collected during 2009 to 2016 in Kuwait by Etest 106 
identified 1 isolate as non-WT while the remaining isolates were WT for AMB. However, among 107 
WT isolates, 7 strains exhibited reduced susceptibility (MIC >1 µg/ml) to AMB (RS-AMB). 108 
These isolates were used for sequence analyses of 3 (ERG2, ERG6 and ERG11) ergosterol 109 
biosynthesis genes to investigate the mechanisms responsible for RS-AMB. Here we describe 110 
novel missense/nonsense mutations in ERG6 and ERG2 in 6 and 2 C. glabrata isolates, 111 
respectively, that resulted in altered sterol content and RS-AMB. 112 
 113 
RESULTS 114 
Characterization of study isolates and antifungal susceptibility. A total of 1646 115 
clinical C. glabrata isolates were received in Mycology Reference Laboratory (MRL), 116 
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Department of Microbiology, Kuwait University during 2009-2016 for species-specific 117 
identification and AST as part of routine patient care. During AST by Etest, 1 isolate was 118 
identified as non-WT while the remaining isolates were WT for AMB. However, among WT 119 
isolates, 7 strains exhibited reduced susceptibility (MIC >1 µg/ml) to AMB (RS-AMB). Thus, 8 120 
isolates exhibited RS-AMB and were included for further studies while the remaining isolates 121 
were considered as WT. Five isolates WT for susceptibility to AMB were analyzed for 122 
comparison purpose. Two other C. glabrata strains isolated in 2012 that required cholesterol (or 123 
other sterols) for growth (20) were not included as their susceptibility to AMB and total cell 124 
sterol content could not be determined accurately. All isolates were identified as C. glabrata by 125 
Vitek 2 yeast identification system and as C. glabrata sensu stricto by MALDI TOF MS and by 126 
PCR amplification of rDNA (data not shown). The results were further confirmed by PCR-127 
sequencing of the ITS region of rDNA which exhibited >99% identity with the corresponding 128 
sequences from two (ATCC90030 and CBS138) reference C. glabrata strains and a well-129 
characterized clinical C. glabrata isolate (Kw280/06) from Kuwait analyzed previously (16), as 130 
expected. The AST data of AMB and other antifungal drugs by the reference broth microdilution 131 
method are presented in Table 1. Eight RS-AMB isolates identified by Etest also exhibited 132 
elevated MICs by broth microdilution method. Other WT isolates showed MICs <0.5 µg/ml for 133 
AMB. Only 1 RS-AMB isolate was resistant to fluconazole and also showed higher MICs for 134 
other triazoles while the remaining isolates were susceptible to triazoles. Interestingly, 4 RS-135 
AMB isolates exhibited very low (<0.5 µg/ml) MICs for fluconazole and other triazoles. Only 1 136 
isolate detected as WT for AMB showed reduced susceptibility to echinocandins while the 137 
remaining isolates were susceptible.  138 
 139 
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Analysis of ERG2, ERG6 and ERG11 gene sequences. Relative to the sequence of 140 
ERG2 protein (C-8 sterol isomerase) from C. glabrata reference strain CBS138 (GenBank 141 
accession number CR380958), several nonsynonymous mutations were identified in the 142 
translated ERG2 protein among clinical isolates analyzed in this study. These included I207V 143 
mutation in all study isolates, G122S mutation only in Kw844/10 and G119S mutation only in 144 
Kw3060/15 (Table 2). The replacement of glycine with serine at Gly122 in C. glabrata 145 
Kw844/10 and at Gly119 in C. glabrata Kw3060/15 apparently impaired ERG2 protein function 146 
as ergosterol was totally absent in these isolates (Table 2). Additionally, some synonymous 147 
mutations within the coding region and nucleotide insertion/deletion/substitution in non-coding 148 
region of ERG2 were also detected in some isolates.  149 
 The results of PCR-sequencing of ERG6 were very interesting as 3 isolates (Kw1856/15, 150 
Kw2813/15 and Kw3357/15) exhibiting RS-AMB contained a nonsense mutation and another 151 
RS-AMB isolate (Kw861/13) contained a deletion of one nucleotide (nucleotide 1021) which 152 
resulted in pre-mature termination of translated protein at codon 341 (Table 2). Although a 153 
nonsynonymous (R48K) mutation was present in some WT and some RS-AMB isolates, 2 other 154 
nonsynonymous mutations (V126F in isolate Kw96/15 and C198F in isolate Kw2516/15) were 155 
detected among 2 RS-AMB isolates only. Interestingly, 5 of 6 RS-AMB isolates cultured in 2015 156 
contained a mutation in ERG6. Compared to the sequence of ERG6 protein (C24 methyl 157 
transferase) from C. glabrata reference strain CBS138 (GenBank accession number CR380954), 158 
some synonymous ERG6 mutations were also detected among the study isolates and the 2 RS-159 
AMB isolates (Kw1856/15 and Kw3357/15) with the same ERG6 mutation (W286*) were 160 
genotypically very different strains. Consistent with PCR-sequencing results, all 6 RS-AMB 161 
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isolates with ERG6 mutations lacked ergosterol and accumulated zymosterol, the substrate for 162 
ERG6.  163 
Relative to the sequence of ERG11 protein (sterol 14α-demethylase) from C. glabrata 164 
reference strain CBS138 (GenBank accession number CR380951), few synonymous mutations 165 
were identified in the translated ERG11 protein among all clinical isolates analyzed in this study 166 
while two nonsynonymous (Y141H + L381M) mutations were detected in one (Kw861/13) RS-167 
AMB isolate (Table 2) that was also resistant to fluconazole (Table 1). Isolate Kw861/13 also 168 
contained ERG6 mutation (deletion of nucleotide 1021 that resulted in creation of termination 169 
codon at Leu341), no detectable ergosterol but higher levels of lanosterol in the cell (Table 2). 170 
None of the other WT or RS-AMB isolates contained a nonsynonymous mutation in ERG11 171 
(Table 2). All mutations were confirmed by re-extraction of DNA from fresh cultures of C. 172 
glabrata isolates and PCR-sequencing of the respective ERG genes. 173 
 174 
Total cell sterol composition. The total cell sterol composition of one isolate WT for 175 
AMB was very similar to the sterol composition of the reference strains ATCC90030 and 176 
Kw280/06 with ergosterol accounting for nearly 90% of total cell sterol. All 6 RS-AMB isolates 177 
with ERG6 mutations showed marked differences in sterol content compared to the isolates WT 178 
for AMB as ergosterol was not detectable while cholesta-type sterols (including zymosterol) 179 
accumulated in the mutants (Table 3). Differences were also apparent in the abundance of 180 
various cholesta-type sterols in the 6 ERG6 mutants. Among the 4 isolates with nonsense 181 
mutations resulting in truncated ERG6 protein, the cholesta-8,24-dienol (zymosterol) was more 182 
abundant sterol in 3 (Kw1856/15, Kw2813/15 and Kw3357/15) isolates while cholesta-5,7,24-183 
trienol was the major accumulating sterol and cholesta-5,7,22,24-tetraenol was barely detectable 184 
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in Kw861/13 (Table 3). The cholesta-5,7,24-trienol was also the major accumulating cholesta-185 
type sterol in 2 (Kw96/15 and Kw2516/15) isolates containing nonsynonymous ERG6 mutations, 186 
however, these isolates also accumulated cholesta-5,7,22,24-tetraenol (Table 3). Isolate 187 
Kw844/10 with a nonsynonymous (G122S) mutation and isolate Kw3060/15 with another 188 
nonsynonymous (G119S) mutation in ERG2 also lacked ergosterol but accumulated ergosta-type 189 
(Δ8) sterols including fecosterol (ergosta-8,24(28)-dienol) (Table 3).  190 
 The genotypic relationship among the study isolates was also determined by constructing 191 
phylogenetic tree based on concatenated sequences of ITS region of rDNA, ERG2, ERG6 and 192 
ERG11 and the results are shown in FIG. 1. Both (Kw844/10 and Kw3060/15) isolates with a 193 
missense mutation in ERG2 and the two (Kw96/15 and Kw2516/15) isolates with a missense 194 
mutation in ERG6 were genotypically distinct strains. Furthermore, all four (Kw861/13, 195 
Kw1856/15, Kw2813/15 and Kw3357/15) isolates with a nonsense mutation in ERG6 were also 196 
unique strains (FIG. 1). Fingerprinting of selected isolates performed with 6-loci-based MLST 197 
also showed that most of the isolates analyzed were unique strains (Table 2). 198 
 199 
DISCUSSION 200 
Invasive fungal infections are difficult to treat due to availability of only few classes of 201 
antifungal agents. Among invasive Candida infections, C. glabrata infections are more common 202 
among elderly (>65-year-old) hospitalized patients who usually have several debilitating 203 
conditions and so these infections are generally associated with higher mortality (24-26). 204 
Although resistance of Candida spp. to azole antifungal drugs is common and resistance to 205 
echinocandins also appeared soon after their introduction in clinical practice nearly 15 years ago, 206 
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RS-AMB is uncommon despite >50 years of clinical use as sequestering of ergosterol by 207 
extramembranous aggregates of amphotericin B deprives phospholipid membranes of a sterol 208 
essential for many different aspects of yeast physiology (8, 9, 11). In diploid C. albicans, RS-209 
AMB is rare due to fitness trade-offs which abrogate fungal virulence (9, 10). However, there 210 
have been several reports of RS-AMB in haploid C. glabrata and breakthrough infections in 211 
patients receiving systemic LAMB is a worrisome development for effective management of 212 
invasive C. glabrata infections (7, 14, 15, 17-19). 213 
 Although molecular mechanisms involved in azole resistance are well recognized, those 214 
involved in conferring RS-AMB are poorly defined (3, 4, 24, 26). Results from this study on 8 C. 215 
glabrata isolates with RS-AMB showed that 4 isolates contained a nonsense mutation at codons 216 
Tyr192 or Trp286 or Leu341 resulting in premature translational termination of ERG6 217 
transcripts. The mutant cells accumulated cholesta-type sterols (including cholesta-8,24-dienol or 218 
zymosterol) indicating that the truncated ERG6 proteins were inactive. Since polyenes act as a 219 
sterol sponge and extract ergosterol from phospholipid bilayer (8, 9), absence of ergosterol in 220 
yeast cell membrane was likely responsible for RS-AMB in these isolates. Nonsense mutations at 221 
codons Tyr192 or Trp286 or Leu341 in ERG6 described in this study are novel mutations 222 
described for the first time. Premature termination of ERG6 protein due to another nonsense 223 
mutation at codon Gln332 was recently described in a C. glabrata isolate with RS-AMB, the 224 
mutant cells lacked ergosterol but accumulated ergosterol pathway intermediates and wild-type 225 
properties were restored in complementation studies with a wild-type copy of the ERG6 gene 226 
(17). The total cell sterol analysis of our isolates also showed differences in the accumulation of 227 
individual cholesta-type sterols in the 4 mutant strains. The mutation in isolate Kw861/13 228 
introduced the stop codon only 32 amino acids before the C-terminal end of C-24 sterol 229 
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methyltransferase encoded by ERG6 while nonsense mutations in the other 3 (Kw1856/15, 230 
Kw2813/15 and Kw3357/15) isolates resulted in shortening of the ERG6 protein by 87 or more 231 
amino acids at the C-terminal end. Previous studies have shown the presence of two conserved 232 
domains in methyltransferases located between amino acid positions 134 to 222 and the second 233 
domain between 231 and the C-terminal end (27, 28). The second domain was only 32 amino 234 
acids shorter in isolate Kw861/13. As ERG6 encoded enzyme catalyzes the conversion of 235 
zymosterol into fecosterol by C-24 methylation, isolate Kw861/13, like the other 3 isolates 236 
lacked fecosterol but unlike the other 3 isolates contained low level of 14-methyl fecosterol 237 
suggesting modification of C-24 sterol methyltransferase activity in Kw861/13. Furthermore, 238 
isolate Kw861/13, in addition to exhibiting RS-AMB, also exhibited resistance to fluconazole 239 
and other azoles, contained two nonsynonymous mutations (Y141H + L381M) in ERG11 and 240 
accumulated lanosterol suggesting loss of sterol 14α-demethylase activity which conferred 241 
resistance to azoles. Fluconazole-resistant clinical C. glabrata isolates usually contain gain-of-242 
function mutations in the gene encoding transcription factor CgPDR1 which results in 243 
upregulation of drug efflux transporters encoded by CgCDR1 and CgCDR2 genes and to a lesser 244 
extent, CgCNQ2 (3, 4). Only few studies have reported azole resistance conferring mutations in 245 
ERG11, the main target of azoles in C. albicans and some other non-albicans Candida species 246 
(3, 4, 18, 29). A clinical C. glabrata isolate (CG156) with a nonsynonymous (G315D) mutation 247 
in substrate recognition site of ERG11 has been described previously that was resistant to 248 
triazoles (fluconazole and voriconazole) and AMB and accumulated lanosterol due to complete 249 
loss of sterol 14α-demethylase activity (18). The mutated CG156 Erg11p failed to complement 250 
the function of a doxycycline-regulatable Saccharomyces cerevisiae erg11 strain while wild-type 251 
C. glabrata Erg11p fully complemented, supporting of role of ERG11 mutation in conferring 252 
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resistance to fluconazole. Another recent study from Iran has also suggested the involvement of 253 
another nonsynonymous mutation (G236V) in ERG11 as the main mechanism conferring 254 
resistance to azoles in a clinical C. glabrata isolate (R1) even though several other 255 
nonsynonymous mutations were also detected in this and other isolates (29). However, the role 256 
of G236V mutation in altering the function of ERG11 was speculated solely based on homology 257 
modelling studies but was not confirmed by sterol analysis or by gene replacement studies (29). 258 
It will be interesting to see if resistance conferring ERG11 mutations are also found in other 259 
fluconazole-resistant C. glabrata isolates in Kuwait. 260 
 Two other RS-AMB isolates contained two different nonsynonymous mutations in 261 
ERG6. Of these V126F mutation in Kw96/15 is a novel mutation while C198F mutation found in 262 
isolate Kw2516/15 has been described previously in an RS-AMB C. glabrata isolate (isolate no. 263 
21229) that lacked ergosterol in cell membrane, exhibited pseudohyphal growth, accumulated 264 
late sterol intermediates and overexpressed genes encoding enzymes involved in late steps of 265 
ergosterol biosynthesis pathway (15). Complementation studies with a wild-type copy of ERG6 266 
gene restored WT pattern of AMB susceptibility for isolate 21229 demonstrating the role of 267 
ERG6 protein in conferring resistance to polyenes (15). Consistent with these observations, 268 
isolate Kw96/15 and Kw2516/15 also lacked ergosterol and accumulated cholesta-type sterols. 269 
As seen above with different nonsense mutations, isolate Kw96/15 and Kw2516/15 also showed 270 
variations in the accumulation of individual intermediates with zymosterol (cholesta-8,24-dienol) 271 
and cholesta-5,7,22,24-tetraenol levels varying by nearly 2-fold and accumulation of detectable 272 
levels of ergosta-5,7-dienol in isolate Kw96/15 but not in isolate Kw2516/15. The findings are 273 
consistent with observations that the enzymes encoded by various ERG genes and involved in 274 
ergosterol biosynthesis pathway may act on similar substrates leading to formation of several 275 
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sterol intermediates (15, 22, 30). Furthermore, similar to isolate 21229 with ERG6 mutation (15), 276 
and an erg1 mutant of C. glabrata (31), both Kw96/15 and Kw2516/15 also exhibited increased 277 
susceptibility to azoles. Similarly, 2 isolates (Kw1856/15 with W286* and Kw2813/15 with 278 
Y192*) with nonsense mutations also exhibited increased susceptibility to azoles while another 279 
isolate (Kw3357/15 with W286*) exhibited slightly higher MIC value for fluconazole. It has 280 
been suggested that isolate 21229 with C198F mutation in ERG6 becomes more susceptible to 281 
azoles due to presence of Δ5,7-dienols (cholesta-type sterols) which maintain the cell viability 282 
but do not completely replace ergosterol functionally (15). Another consequence of altered sterol 283 
composition in the mutant cells is disturbance of protein trafficking preventing targeting of ABC 284 
transporters (CgCDR1p and CgCDR2p) to the plasma membrane and the decreased efflux 285 
capacity likely contributes to increased sensitivity to azoles (15, 32).  286 
 Although a nonsynonymous mutation (I207V) was found in ERG2 in all 13 C. glabrata 287 
isolates from Kuwait, this alteration represents genetic polymorphism not associated with RS-288 
AMB since it has also been described previously in C. glabrata isolates WT for AMB as well as 289 
in isolates with RS-AMB (19). However, 2 RS-AMB (Kw844/10 and Kw3060/15) C. glabrata 290 
isolates from Kuwait contained novel nonsynonymous mutations (G122S and G119S) in ERG2. 291 
Both isolates (Kw844/10 and Kw3060/15) lacked ergosterol and accumulated ergosta-type 292 
sterols including fecosterol (Δ8 sterols). Two RS-AMB C. glabrata isolates containing 293 
nonsynonymous mutations at ERG2 codon Thr121 (T121I and T121V) have been described 294 
recently (19). Both ERG2 mutant isolates (CG852 and CG872) in that study (19) also lacked 295 
ergosterol and accumulated Δ8 sterols indicating impaired function of ERG2 protein. Thr121 in 296 
ERG2 protein is likely involved in the binding of sterol substrate as the corresponding amino 297 
acid (Thr119) in S. cerevisiae is involved in sterol Δ8-Δ7 isomerization (19, 33). Since Gly119 298 
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and Gly122 are located on either side of the Thr121, they may be critical in maintaining the 299 
structure of the active site and the extended region (codons 119 to 122) may constitute the ERG2 300 
protein region conferring RS-AMB. 301 
An intriguing observation of our study pertains to the fact that despite complete absence 302 
of ergosterol from mutant C. glabrata cells, the increase in MIC values for AMB were only 303 
modest as they were still categorized within WT category for susceptibility to AMB. These 304 
observations and the presence of significant amounts of various ergosta-type and cholesta-type 305 
sterols in mutant C. glabrata cells suggest that at least some of these sterols can also maintain 306 
fungal membrane fluidity and are also sensitive to removal by the extramembranous AMB 307 
sponge. It will be interesting to see how these mutant strains will respond to other derivatives of 308 
AMB that have recently been synthesized to overcome the problem of toxicity of AMB to 309 
mammalian cells (9, 34, 35).  310 
 Fingerprinting of the isolates carried out by sequence comparisons of ITS region of 311 
rDNA together with ERG2, ERG6 and ERG11 sequences showed that all study isolates were 312 
genotypically distinct strains. The 6-loci-based MLST carried out on selected RS-AMB isolates 313 
also showed genetic variations among the isolates as they usually belonged to different STs. 314 
These findings suggest that RS-AMB in C. glabrata isolates in Kuwait is not clonal. 315 
In conclusion, 8 RS-AMB C. glabrata strains were isolated in Kuwait and 6 of these 8 316 
isolates were obtained in 2015. Six isolates contained a nonsense or nonsynonymous mutation in 317 
ERG6 while 2 isolates contained a nonsynonymous mutation in ERG2 and the total cell sterol 318 
content were consistent with ERG6 or ERG2 deficiency. Fingerprinting studies showed that RS-319 
AMB in C. glabrata isolates in Kuwait was not clonal. The data show that ERG6 and ERG2 are 320 
major targets conferring RS-AMB in clinical C. glabrata isolates. 321 
16 
 
 322 
MATERIALS AND METHODS 323 
Yeast strains, culture conditions and identification. Reference strains of Candida 324 
glabrata (ATCC90030, CBS138 and a well characterized clinical isolate, Kw280/06) were used. 325 
During 2009 to 2016, 1646 clinical C. glabrata isolates were received in the Mycology 326 
Reference Laboratory (MRL), Department of Microbiology, Faculty of Medicine, Kuwait 327 
University. The isolates were cultured in BACTEC Plus blood culture bottles (Beckton 328 
Dickinson, Sparks, MD, USA) from various clinical specimens in different hospitals across 329 
Kuwait after obtaining informed verbal consent as part of routine patient care and diagnostic 330 
work-up. The isolates were initially subcultured at MRL on Sabouraud dextrose agar (SDA) for 331 
species-specific identification and antifungal susceptibility testing (AST) as part of routine 332 
patient care (16). Few isolates failed to grow on SDA upon subculturing and required addition of 333 
cholesterol to SDA for their growth, as described in detail previously (20). 334 
Phenotypic identification of the isolates was initially performed by Vitek 2 yeast 335 
identification system (bioMérieux, Marcy-l’Etoile, France). The isolates were also identified by 336 
matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI TOF MS) 337 
as described previously (36). The genomic DNA from reference strains and clinical isolates was 338 
extracted by using Gentra Puregene Yeast DNA extraction kit (Qiagen, Hilden, Germany) 339 
according to kit instructions or by the rapid method using Chelex-100, as described previously 340 
(37). Species-specific identification was performed by PCR amplification of rDNA as described 341 
previously (38). The complete ITS region was also amplified by using ITS1 and ITS4 primers 342 
and the amplicons were sequenced by using ITS1FS, ITS2, ITS3 and ITS4RS primers, as 343 
described previously (39, 40).  344 
17 
 
 345 
Antifungal susceptibility testing. The antifungal susceptibility testing (AST) of C. 346 
glabrata isolates to AMB was initially carried out on SDA and minimum inhibitory 347 
concentrations (MICs) were determined by the Etest procedure (AB Biodisk, Solna, Sweden) 348 
according to manufacturer’s instructions and as described previously (41). The isolates were also 349 
tested against different antifungal drugs by the CLSI reference broth microdilution method as 350 
described previously (42, 43) and susceptibility breakpoints for different antifungal agents were 351 
those described earlier (23, 43, 44). C. glabrata ATCC90030 was used as reference strain during 352 
AST. 353 
 354 
ERG genes sequencing. The complete coding sequence and the flanking 5’ and 3’ 355 
untranslated regions of ERG2, ERG6 and ERG11 genes for all study isolates were amplified 356 
from genomic DNA by using gene-specific primers. The ERG2 gene was amplified by using 357 
CgERG2F (5’-CTAAACGAGCTCGTAATTCTA-3’) and CgERG2R (5’-358 
GCCTTAGAGTCTATCCTTGAA-3’) primers by using the PCR amplification reaction and 359 
cycling conditions, as described previously (37, 39). The amplicons were purified by using PCR 360 
product purification kit (Qiagen, Hilden, Germany) according to kit instructions. Both strands of 361 
purified amplicons were sequenced by using forward (CgERG2FS1, 5’-362 
GCTCGTAATTCTATCGGTTTGA-3’; CgERG2FS2, 5’-TTGCAATGGTGTACTTGCCAA-3’; 363 
CgERG2FS3, 5’-GGTATGACCCATCATCTACA-3’) and reverse (CgERG2RS1, 5’-364 
GATTCTGTAGAGGCACTAGCA-3’; CgERG2RS2, 5’-CCTTGAGCCAATTCTAGTGCGA-365 
3’; CgERG2RS3, 5’-CCTTAGAGTCTATCCTTGAATTA-3’) primers with BigDye terminator 366 
v3.1 cycle sequencing kit (Applied Biosystems, Austin, TX, USA) and ABI 3130xl Genetic 367 
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Analyzer by following manufacturer’s instructions (Applied Biosystems) and as described 368 
previously (20, 37). The complete ERG2 sequences of ~1060 bp were assembled and were 369 
compared with the corresponding sequences from reference C. glabrata strain CBS138 by using 370 
the program Clustal omega (https://www.ebi.ac.uk/Tools/msa/clustalo/). 371 
The ERG6 gene was amplified and sequenced as two overlapping fragments. The N-372 
terminal fragment was amplified by using CgERG6F1 (5’-GATTTTCTCGTTTCGCCGAGAA-373 
3’) and CgERG6R1 (5’-GATGATGTTACAGCCGGTGAA-3’) primers while the C-terminal 374 
fragment was amplified by using CgERG6F2 (5’-ACGAACAGTACTTGGCATACA-3’) and 375 
CgERG6R2 (5’-CATGTGGAATGAATTCAAGTGA-3’) primers and PCR amplification 376 
reaction and cycling conditions, as described previously (37, 39). The amplicons were purified 377 
and both strands were sequenced by using the gene-specific primers and the sequencing protocol 378 
described previously (20, 37). The sequencing primers for the N-terminal fragment included 379 
forward (CgERG6FS1, 5’-CTCGTTTCGCCGAGAATTGTTA-3’ or CgERG6FS2, 5’-380 
CAGTTTATTGTGCTCTTGACG-3’) and reverse (CgERG6RS1, 5’-381 
TCGGGAGAATTTCAATTCCTT-3’ or CgERG6RS2, 5’-GATGTTACAGCCGGTGAATCT-382 
3’) primers. The primers for the C-terminal fragment included forward (CgERG6FS3, 5’-383 
GAACAGTACTTGGCATACATGG-3’ or CgERG6FS4, 5’-TTTGAAGAACGTCGGTTTCG-384 
3’) and reverse (CgERG6RS3, 5’-GTACTTCCATTCTCCGGTCAA-3’ or CgERG6RS4, 5’-385 
GTGGAATGAATTCAAGTGAACA-3’) primers. The complete ERG6 sequences of ~1840 bp 386 
were assembled and were compared with the corresponding sequences from reference C. 387 
glabrata strain CBS138 by using the program Clustal omega 388 
(https://www.ebi.ac.uk/Tools/msa/clustalo/).  389 
19 
 
The ERG11 was amplified and sequenced from all study isolates as described previously 390 
(20). The complete ERG11 sequences of ~1920 bp were assembled and were compared with the 391 
corresponding sequences from reference C. glabrata strain CBS138 by using Clustal omega. 392 
 393 
Fingerprinting of C. glabrata isolates. The gene sequences were analyzed individually 394 
or nucleotide sequences of ERG2, ERG6 and ERG11 genes together with ITS region of rDNA 395 
were included in the combined analysis. Multiple sequence alignments of concatenated sequence 396 
data were performed with Clustalw muscle (https://www.ebi.ac.uk/Tools/msa/muscle/) and 397 
phylogenetic analysis was performed with Molecular Evolutionary Genetic Analysis (MEGA) 398 
version 6 software. The phylogenetic tree was constructed using the Neighbor-joining method 399 
with Kimura 2-parameter model. The DNA sequence data from C. glabrata strain CBS138 was 400 
used as reference and the robustness of tree branches was assessed by bootstrap analysis with 401 
1,000 replicates. The genotypic relationship among selected C. glabrata isolates was also studied 402 
by 6 (FKS, LEU2, NMT1, TRP1, UGP1 and URA3) loci-based multilocus sequence typing 403 
(MLST) scheme, as described previously (45). The DNA sequences for each gene fragment were 404 
used for allelic profile and the combined data set were used to determine the sequence types 405 
(STs) (45). Since a curated MLST database is not available for C. glabrata, new STs from 406 
Kuwait were given an arbitrary number (STKN1, STKN2 etc).  407 
 408 
Sterol analysis. The total cell sterol content of C. glabrata isolates was determined by 409 
inoculating 15-ml volumes of MOPS-buffered (0.165 M MOPS) RPMI medium (pH 7.0) with 410 
single colonies and the cultures were grown for 24 h at 37oC. Cells were harvested by 411 
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centrifugation and washed three times with sterile water before sterol extraction. Non-412 
saponifiable lipids were extracted by using alcoholic KOH as described previously (46). Samples 413 
were dried in a vacuum centrifuge (Heto) and were derivatized with trimethylsilane (TMS) by 414 
the addition of 100 µl of 90% N,O-Bis (trimethylsilyl) trifluoroacetamide (BSTFA)/10% TMS 415 
(Sigma), 200 µl anhydrous pyridine (Sigma) and heating for 2 h at 80oC. The TMS-derivatized 416 
sterols were analyzed by using gas chromatography-mass spectrometry (GC-MS) (Thermo 1300 417 
GC coupled to a Thermo ISQ mass spectrometer, Thermo Scientific, Loughborough, UK) and 418 
identified with reference to retention times and fragmentation spectra for known standards (18, 419 
46). The GC/MS data files were analyzed by using Xcalibur software (Thermo Scientific) to 420 
determine sterol profiles for study isolates and for integrated peak areas. The results of three 421 
replicates from each sample were used to calculate the mean percentage + standard deviation for 422 
each sterol. 423 
 424 
Patient samples. The clinical specimens which yielded the C. glabrata isolates described 425 
in this study were obtained from different patients after obtaining informed verbal consent as part 426 
of routine patient care and diagnostic work-up. The isolates were also analyzed in the Mycology 427 
Reference Laboratory in the Department of Microbiology, Faculty of Medicine, Kuwait 428 
University, for identification and antifungal susceptibility testing as part of routine patient care, 429 
and the results from deidentified samples are described in this paper. 430 
 431 
Accession numbers. The DNA sequence data reported in this study have been submitted 432 
to GenBank under accession numbers LS398111 to LS398136, LS398591 to LS398603 and 433 
LS399273 to LS399285. 434 
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TABLE 1 Source of isolation and minimum inhibitory concentration (MIC) values of 13 C. glabrata isolates for amphotericin B 579 
(AMB) by Etest and for AMB and other antifungal drugs by broth microdilution method  580 
Isolate Clinical  AMB MIC (µg/ml)                         MIC values (µg/ml) by broth microdilution method for   
no. specimen by Etest AMB FLC ITC VOR POS ISA ANI MIC 
ATCC90030a N. A. 0.094 0.5 4 0.125 0.125 0.25 0.125 0.016 <0.008 
Kw280/06a Vaginal swab 0.047 0.5 16 0.5 0.25 0.25 0.5 0.031 <0.008 
Kw600/09 Wound swab 0.032 N. D. N. D. N. D. N. D. N. D. N. D. N. D. N. D. 
Kw164/15 Urine 0.38 0.25 16 0.25 0.25 0.25 0.125 0.5 0.125 
Kw383/15 Ascitic fluid 0.19 0.5 2 0.125 0.031 0.125 0.031 0.016 <0.008 
Kw590/15 Sputum 0.003 0.25 16 0.25 0.25 0.25 0.125 0.016 <0.008 
Kw1421/16 Bone 0.25 0.5 1 0.063 0.031 0.063 0.016 0.031 <0.008 
Kw844/10 Urine 1.5 1 2 0.125 0.031 0.125 0.031 0.031 <0.008 
Kw861/13 ET aspirate 1 1 >64 0.5 2 0.25 0.5 0.016 <0.008 
Kw96/15 Urine 2 1 0.5 0.063 <0.016 0.063 <0.016 0.031 <0.008 
Kw1856/15 Urine 1.5 1 0.25 0.125 <0.016 0.125 <0.016 0.016 <0.008 
Kw2516/15 Urine 1.5 1 0.5 0.063 0.031 0.125 0.016 0.016 <0.008 
Kw2813/15 Urine 4 1 0.25 0.031 <0.016 0.031 <0.016 0.016 <0.008 
Kw3060/15 Wound swab 1.5 1 1 0.063 <0.016 0.063 <0.016 0.031 <0.008 
Kw3357/15 Urine 2 1 2 0.5 0.125 0.25 0.016 0.031 0.016 
aC. glabrata strains ATCC90030 and Kw280/06 were used as reference strains 581 
ET aspirate, endotracheal aspirate; MIC, minimum inhibitory concentration; AMB, amphotericin B; FLC, fluconazole; ITC, itraconazole; VOR, voriconazole; 582 
POS, posaconazole; ISA, isavuconazole; ANI, anidulafungin; MIC, micafungin; N. A., not available; N. D., not done 583 
  584 
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TABLE 2 Susceptibility to amphotericin B (AMB), mutations detected in ERG2, ERG6 and ERG11 genes, fingerprinting by ITS-585 
ERG2-ERG6-ERG11 sequence-based profile and by 6-loci-based sequence types and content of ergosterol, fecosterol, zymosterol and 586 
lanosterol as a percentage of total cell sterol in 13 C. glabrata isolates 587 
Isolate Clinical  Susceptibility         Non-synonymous mutations detected in  ITS-ERG2-ERG6- MLST-              % of total cell sterol detected as    
no. specimen to AMBa ERG2 ERG6 ERG11 ERG11-based profile based STs Ergosterol Fecosterol Zymosterol Lanosterol 
ATCC90030 N. A. Wild-type Referenceb Referenceb Referenceb Referencea N. D. 93.0 + 0.1 1.0 + 0.0 0 1.3 + 0.1 
Kw280/06 Vaginal swab Wild-type I207V R48K None Unique ST-KN1 84.8 + 2.8 2.0 + 0.3 2.5 + 0.6 3.2 + 0.3 
Kw600/09 Wound swab Wild-type I207V None None Unique N. D. N. D. N. D. N. D. N. D. 
Kw164/15 Urine Wild-type I207V None None Unique N. D. N. D. N. D. N. D. N. D. 
Kw383/15 Ascitic fluid Wild-type I207V R48K None Unique N. D. N. D. N. D. N. D. N. D. 
Kw590/15 Sputum Wild-type I207V R48K None Unique N. D. N. D. N. D. N. D. N. D. 
Kw1421/16 Bone Wild-type I207V None None Unique N. D. 89.5 + 7.2 2.1 + 1.6 0 0.2 + 0.2 
Kw844/10 Urine RS-AMB I207V + G122S None None Unique N. D. 0 14.9 + 2.2 0 2.5 + 0.1 
Kw861/13 ET aspirate RS-AMB I207V Δ Nt. 1021, L341* Y141H + L381M Unique ST-KN2 0 0 21.4 + 0.8 11.6 + 1.0 
Kw96/15 Urine RS-AMB I207V V126F None Unique ST-46 0 0 14.5 + 0.5 0.6 + 0.1 
Kw1856/15 Urine RS-AMB I207V W286* None Unique ST-46 0 0 42.5 + 1.3 3.3 + 0.3 
Kw2516/15 Urine RS-AMB I207V R48K + C198F None Unique ST-KN3 0 0 35.5 + 0.6 1.3 + 0.2 
Kw2813/15 Urine RS-AMB I207V Y192* None Unique ST-KN4 0 0 42.7 + 0.4 2.4 + 0.1 
Kw3060/15 Wound swab RS-AMB I207V + G119S None None Unique N. D. 0 18.9 + 2.3 0 1.2 + 0.3 
Kw3357/15 Urine RS-AMB I207V W286* None Unique N. D. 0 0 45.4 + 1.0 2.1 + 0.3 
aC. glabrata isolates with MIC values < 0.5 µg/ml were classified as wild-type for AMB while those with MIC values > 1 µg/ml were classified as isolates with 588 
reduced susceptibility to AMB (RS-AMB) 589 
 bC. glabrata strain ATCC90030 was used as reference strain for susceptibility to amphotericin B (AMB) and strain CBS138 was used as reference strain for 590 
ERG gene sequencing 591 
*Denotes a nonsense mutation; ST, sequence type; ST-KN, new sequence type detected in Kuwait; N. D., not done 592 
Sterol values (mean of 3 replicates with standard deviation) are percentage of total sterols and values >5% of total cell sterol are shown in bold.  593 
30 
 
TABLE 3 Total C. glabrata cell sterol composition in an isolate (Kw1421/16) wild-type for AMB and 7 isolates with reduced 594 
susceptibility to AMB 595 
Type of                                        Percentage of each sterol in the total cell sterol composition of C. glabrata isolate no.                       
sterol ATCC90030a Kw280/06a Kw1421/16 Kw844/10 Kw861/13 Kw96/15 Kw1856/15 Kw2516/15 Kw2813/15 Kw3060/15 Kw3357/15 
Ergosta-5,8,22,24-tetraenol 0.9 + 0.1 3.4 + 1.2 0.7 + 0.1 1.5 + 0.0           1.2 + 0.3   
Unknown sterol        1.4 + 0.1 1.4 + 0.0 0.9 + 0.1 1.2 + 0.0 1.0 + 0.1   0.9 + 0.0 
Ergosta-5,8,22-trienol 0.9 + 0.0 1.0 + 0.0 0.4 + 0.3 25.8 + 0.3           31.6 + 1.1   
Ergosta-8,22-dienol       7.0 + 0.7           8.3 + 0.2   
Ergosta-5,8,24-trienol       8.2 + 0.5           8.0 + 1.4   
Ergosta-5,8-dienol       6.0 + 0.4           1.3 + 0.1   
Cholesta-5,8,24-trienol         5.1 + 0.3 9.0 + 0.3 5.2 + 0.5 9.5 + 0.5 6.0 + 0.4   6.5 + 0.1 
Zymosterol (Cholesta-8,24-dienol)   2.5 + 0.6     21.4 + 0.8 14.5 + 0.5 42.5 + 1.3 35.5 + 0.6 42.7 + 0.4   45.4 + 1.0 
Cholesta-5,7,24-trienol 1.1 + 0.0   1.6 + 1.3   56.0 + 0.4 40.9 + 0.5 34.0 + 0.2 36.9 + 0.7 35.2 + 0.3   36.3 + 1.3 
Ergosterol 93.0 + 0.1 84.8 + 2.8 89.5 + 7.2                 
Cholesta-7,24-dienol         1.3 + 0.5 1.0 + 0.1 1.9 + 0.3 0.8 + 0.0 1.4 + 0.1   1.0 + 0.0 
Cholesta-5,7,22,24-tetraenol         0.1 + 0.2 26.7 + 0.9 11.5 + 0.8 13.6 + 1.6 10.3 + 0.5   6.8 + 0.4 
14-Methyl fecosterol         1.0 + 0.0             
Fecosterol (Ergosta-8,24(28)-dienol) 1.0 + 0.0 2.0 + 0.3 2.1 + 1.6 14.9 + 2.2           18.9 + 2.3   
Ergosta-8-enol       30.9 + 1.3           29.5 + 0.9   
Ergosta-5,7-dienol 1.3 + 0.2 1.8 + 0.1 2.2 + 1.7   0.3 + 0.3 5.9 + 0.3     0.4 + 0.1   0.6 + 0.1 
Episterol (Ergosta-7,24(28)-dienol) 0.2 + 0.0 0.7 + 0.1 1.2 + 0.9                 
Unknown sterol       2.1 + 0.3       0.7 + 0.2       
14-Methyl ergosta-8,24(28)-dien-3,6-diol                       
Lanosterol 1.3 + 0.1 3.2 + 0.3 2.1 + 1.6 2.5 + 0.1 11.6 + 1.0 0.6 + 0.1 3.3 + 0.3 1.3 + 0.2 2.4 + 0.1 1.2 + 0.3 2.1 + 0.3 
4,4-Dimethyl cholesta-8,24-dienol 0.2 + 0.1 0.6 + 0.4 0.2 + 0.2 1.1 + 0.1 1.9 + 0.2   0.8 + 0.2 0.4 + 0.1 0.7 + 0.0   0.3 + 0.0 
 aC. glabrata strains ATCC90030 and Kw280/06 were used as reference strain for determining total cell sterol composition; AMB, amphotericin B 596 
Sterol values (mean of 3 replicates with standard deviation) are percentage of total sterols and values >5% of total cell sterol are shown in bold  597 
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FIGURE legend: 598 
FIG. 1. Neighbor-joining phylogenetic tree based on combined sequence data for ITS region of 599 
rDNA, ERG2, ERG6 and ERG11 genes from 13 clinical C. glabrata isolates from Kuwait 600 
together with reference C. glabrata strains CBS138 and Kw280/06. The numbers on the nodes 601 
branches are bootstrap frequencies. 602 
  603 
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